The effects of synbiotics on indoxyl sulphate level, constipation, and quality of life associated with constipation in chronic haemodialysis patients: a randomized controlled trial

Aida Lydia, Tities Anggraeni Indra, Aulia Rizka, Murdani Abdullah, Aida Lydia, Tities Anggraeni Indra, Aulia Rizka, Murdani Abdullah

Abstract

Background: Gut microbiota dysbiosis in patients with chronic kidney disease on haemodialysis (CKD-HD) creates an increase in proteolytic bacteria activity, leading to an increase in the production of uraemic toxins, such as indoxyl sulphate, worsening of constipation symptoms and reducing patients' quality of life. Improving gut microbiota dysbiosis is expected to improve this condition. This study aimed to evaluate the effect of synbiotics on indoxyl sulphate levels, constipation symptoms, and constipation-related quality of life in haemodialysis patients.

Methods: This was a double-blinded randomized controlled clinical trial with a parallel design involving haemodialysis patients. We included chronic haemodialysis patients with gastrointestinal complaints, difficulty defecating, faeces with hard consistency, or a bowel movement frequency of fewer than three times per week. Patients were randomly divided into two groups (synbiotics (Lactobacillus acidophilus and Bifidobacterium longum 5x109 CFU) and placebo) for 60 days of oral intervention. All participants, caregivers, and outcome assessors were blinded to group assignment. The primary outcome was a decrease in indoxyl sulphate toxin levels. Meanwhile, improvement in constipation symptoms (measured using the Patient Assessment of Constipation: Symptoms (PAC-SYM) questionnaire) and improvement in constipation-related quality of life (measured using the Patient Assessment of Constipation Quality of Life (PAC-QOL) questionnaire) were assessed as secondary outcomes.

Results: We included 60 patients (30 intervention; median age of 51.23 (13.57) years, 33.3% male; 30 control; median age of 52.33 (11.29) years, 36.7% male). There was no significant difference in terms of pre- and postintervention indoxyl sulphate toxin levels in the synbiotics group compared to the placebo group (p=0.438). This study found an improvement in constipation symptoms (p = 0.006) and constipation-related quality of life (p=0.001) after synbiotic administration.

Conclusion: Two months of synbiotic supplementation did not lower indoxyl sulphate toxin levels. Nevertheless, it had a major effect in improving constipation and quality of life affected by constipation in patients undergoing chronic haemodialysis.

Trial registration: NCT04527640 (date of first registration: 26/08/2020).

Keywords: Chronic kidney disease; Constipation; Haemodialysis; Indoxyl sulphate; Quality of life; Synbiotics.

Conflict of interest statement

The authors have no conflicts of interest to declare.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Research algorithm according to Consolidated Standards of Reporting Trials (CONSORT)

References

    1. Armani R, Ramezani A, Yasir A, et al. Gut microbiome in chronic kidney disease. Curr Hypertens Rep. 2017;19(4):29. doi: 10.1007/s11906-017-0727-0.
    1. Rukavina Mikusic NL, Kouyoumdzian NM, Choi MR. Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis. Pflugers Arch Eur J Physiol. 2020;472:303–320. doi: 10.1007/s00424-020-02352-x.
    1. Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ Res. 2012;111(11):1470–1483. doi: 10.1161/CIRCRESAHA.112.278457.
    1. Ramezani A, Massy ZA, Meijers B, et al. Role of the gut microbiome in Uremia: A potential therapeutic target. Am J Kidney Dis. 2016;67:483–498. doi: 10.1053/j.ajkd.2015.09.027.
    1. Zuvela J, Trimingham C, Le Leu R, et al. Gastrointestinal symptoms in patients receiving dialysis: A systematic review. Nephrology. 2018;23:718–727. doi: 10.1111/nep.13243.
    1. Ikee R, Yano K, Tsuru T. Constipation in chronic kidney disease: It is time to reconsider. Ren Replace Ther. 2019;5:51. doi: 10.1186/s41100-019-0246-3.
    1. Zhang J, Huang C, Li Y, et al. Health-related quality of life in dialysis patients with constipation: A cross sectional study. Patient Prefer Adherence. 2013;7:589–594.
    1. Nakabayashi I, Nakamura M, Kawakami K, et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: A preliminary study. Nephrol Dial Transplant. 2011;26:1094–1098. doi: 10.1093/ndt/gfq624.
    1. Rossi M, Johnson DW, Morrison M, et al. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): A randomized trial. Clin J Am Soc Nephrol. 2016;11:223–231. doi: 10.2215/CJN.05240515.
    1. Guida B, Germanò R, Trio R, et al. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: A randomized clinical trial. Nutr Metab Cardiovasc Dis. 2014;24:1043–1049. doi: 10.1016/j.numecd.2014.04.007.
    1. Cruz-Mora J, Martínez-Hernández NE, Martín del Campo-López F, et al. Effects of a Symbiotic on Gut Microbiota in Mexican Patients With End-Stage Renal Disease. J Ren Nutr. 2014;24:330–335. doi: 10.1053/j.jrn.2014.05.006.
    1. Abdullah M, Maulahela H, Utari AP, Kusumo PD, Soebandrio A, et al. Patient assessment of constipation quality of life questionnaire: validity and reliability for Indonesian population. Med J Indones. 2019;28:345–350. doi: 10.13181/mji.v28i4.3353.
    1. Abdullah M, Maulahela H, Utari AP, Kusumo PD, Soebandrio A, et al. Validity and Reliability of the Patient Assessment of Constipation: Symptoms (PAC-SYM) in the Indonesian Language. IOP Conf Ser: Earth Environ Sci. 2019;248:012060. .
    1. Leong SC, Sirich TL. Indoxyl sulfate-review of toxicity and therapeutic strategies. toxins (Basel). 2016;8(12):358. .
    1. Meyer TW, Peattie JW, Miller JD, et al. Increasing the clearance of protein-bound solutes by addition of a sorbent to the dialysate. J Am Soc Nephrol. 2007;18(3):868–874. doi: 10.1681/ASN.2006080863.
    1. Krieter DH, Hackl A, Rodriguez A, et al. Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. Nephrol Dial Transplant. 2010;25(1):212–218. doi: 10.1093/ndt/gfp437.
    1. Meert N, Waterloos MA, Van Landschoot M, et al. Prospective evaluation of the change of predialysis protein-bound uremic solute concentration with postdilution online hemodiafiltration. Artif Organs. 2010;34(7):580–585. doi: 10.1111/j.1525-1594.2010.01005.x.
    1. Cosola C, Rocchetti MT, Di Bari I, et al. An innovative synbiotic formulation decreases free serum indoxyl sulfate, small intestine permeability and ameliorates gastrointestinal symptoms in a randomized pilot trial in stage IIIb-IV CKD patients. Toxins (Basel). 2021;13(5):334. .
    1. Nguyen TTU, Kim HW, Kim W. Effects of Probiotics, Prebiotics, and Synbiotics on Uremic Toxins, Inflammation, and Oxidative Stress in Hemodialysis Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2021;10(19):4456. doi: 10.3390/jcm10194456.
    1. McFarlane C, Krishnasamy R, Stanton T, Emma S, Matthew S, Mihala G, et al. Synbiotics Easing Renal Failure by Improving Gut Microbiology II (SYNERGY II): A Feasibility Randomized Controlled Trial. Nutrients. 2021;13:4481. doi: 10.3390/nu13124481.
    1. Hewadmal N, Jangra S. A Review on Probiotic and Health Benefits of Probiotics. Int J Curr Microbiol App Sci. 2019;8:1863–1880. doi: 10.20546/ijcmas.2019.805.218.
    1. Guarino MPL, Altomare A, Emerenziani S, et al. Mechanisms of action of prebiotics and their effects on gastro-intestinal disorders in adults. Nutrients. 12. Epub ahead of print 2020:10.3390/nu12041037.
    1. Sumida K, Yamagata K, Kovesdy CP. Constipation in CKD. Kidney Int Reports. 2020;5:121–134. doi: 10.1016/j.ekir.2019.11.002.
    1. Nishiyama K, Aono K, Fujimoto Y, et al. Chronic kidney disease after 5/6 nephrectomy disturbs the intestinal microbiota and alters intestinal motility. J Cell Physiol. 2019;234:6667–6678. doi: 10.1002/jcp.27408.
    1. Ramos CI, Armani RG, Canziani ME, et al. Bowel Habits and the Association With Uremic Toxins in Non–Dialysis-Dependent Chronic Kidney Disease Patients. J Ren Nutr. 2020;30:31–35. doi: 10.1053/j.jrn.2019.02.004.
    1. Ikee R, Sasaki N, Yasuda T, et al. Chronic kidney disease, gut dysbiosis, and constipation: A burdensome triplet. Microorganisms. 2020;8:1–18. doi: 10.3390/microorganisms8121862.
    1. Salmean YA, Segal MS, Palii SP, et al. Fiber supplementation lowers plasma p-cresol in chronic kidney disease patients. J Ren Nutr. 2015;25:316–320. doi: 10.1053/j.jrn.2014.09.002.
    1. Zhao Y, Yu YB. Intestinal microbiota and chronic constipation. Springerplus. 2016;5:1130. doi: 10.1186/s40064-016-2821-1.
    1. Ranganathan N, Ranganathan P, Friedman EA, et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther. 2010;27:634–647. doi: 10.1007/s12325-010-0059-9.
    1. Haghighat N, Mohammadshahi M, Shayanpour S, et al. The effect of synbiotic and probiotic supplementation on mental health parameters in patients undergoing hemodialysis: A double-blind, randomized, placebo-controlled trial. Indian J Nephrol. 2021;31:149–156. doi: 10.4103/ijn.IJN_341_19.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa